Navigation Links
InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
Date:7/7/2011

BRISBANE, Calif., July 7, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF).  ASCEND is a multinational, randomized, double-blind, placebo controlled Phase 3 trial designed to evaluate the safety and efficacy of Esbriet® (pirfenidone) in IPF patients with mild to moderate impairment in lung function.  The primary endpoint is lung function, as measured by change in forced vital capacity (FVC) from baseline to Week 52.  The trial will enroll a total of approximately 500 patients who will be randomly assigned 1 to 1 to receive oral pirfenidone (2403 mg/day) or placebo.  Patients will be enrolled at centers in the United States, Mexico, South America, Australia and New Zealand.  

Steve Porter, M.D., Ph.D., Chief Medical Officer of InterMune, said, "We are very pleased to report enrollment of the first patient in ASCEND.  This study represents our continued commitment to making Esbriet available for the more than 100,000 IPF patients in the United States who are afflicted with IPF but currently have no FDA-approved therapies available to them."  

ASCEND Phase 3 Trial

InterMune's new Phase 3 study of pirfenidone is named ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF).  ASCEND will add to pirfenidone's body of clinical evidence and support a future submission for FDA approval.

InterMune expects the trial to be fully enrolled by the first half of 2012, and that results from the study will be available in mid-2013.  InterMune anticipates a New Drug Application (NDA) resubmission for pirfenidone in the second half of 2013 and an FDA action in the first half of 2014.  

Relative to InterMune's previous studies o
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell Lindgren ... month on his first mission to the International Space ... 8 to 9 a.m. EDT Tuesday, July 7. ... Star City, Russia . The interviews will ... Television highlighting his mission training. To schedule an ...
(Date:6/30/2015)... 2015  Today, Americord Registry, one of the fastest growing ... , a partner at Kirkland & Ellis LLP, as the ... - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about ... Martin Smithmyer , CEO of Americord. "He brings a ... will assist Americord,s growth and vision." Andrew ...
(Date:6/30/2015)... ... 2015 , ... With its latest polyacrylonitrile (PAN) membrane, Sterlitech ... flow rates in comparison to nylon or polyethersulfone (PES). Its unique nanofiber ... liquid flow while trapping particulates as small as 0.2 micron in width. , ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... Sigma Life Science, the innovative biological ... SIAL ), today announced that its SAGE Labs initiative ... (ZFN) technology to generate knock-in rats in which foreign ... genome in a precisely targeted manner.  This breakthrough achievement ...
... QuantaLife, Inc. announced today that it ... of the proceeds will be used to establish commercial ... Digital™ PCR platform, into the life sciences research market ... tests. Paladin Capital Group, together with other existing investors ...
... YORK, Dec. 10, 2010 Ramius V&O Acquisition LLC, ... that it has sent a letter to the Board ... CYPB ) outlining its willingness to acquire all of ... $5.50 per share.  The offer is conditioned upon Cypress ...
Cached Biology Technology:Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 2Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 3Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 4QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital™ PCR Platform and Establish Commercial Operations by 2011 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... 2013 -- An important new study has revealed the ... influences gene expression profiles of breast cancer. The ... measurements may benefit from pooling of biopsies from a ... Cancer Conference in Brussels, Belgium. These findings represent ...
... Harbor, NY When a pedestrian hears the screech of a ... to move in response. Is the action taking place blocks ... truly primal mechanisms that we depend on every day of our ... sense of hearing -- is yielding its secrets to modern neuroscience. ...
... spill in the Gulf of Mexico, crude oil toxicity ... according to new findings from a research team that ... researchers from Louisiana and South Carolina, the scientists found ... locations show developmental abnormalities, including heart defects, delayed hatching ...
Cached Biology News:Study reveals magnitude of variation in gene expression measurements within breast cancers 2Study reveals magnitude of variation in gene expression measurements within breast cancers 3Scientists discover how brain's auditory center transmits information for decisions, actions 2Scientists discover how brain's auditory center transmits information for decisions, actions 3Health defects found in fish exposed to Deepwater Horizon oil spill 2
... tubes for rodent oral gavage feature soft ... perforation and trauma. Plus they are disposable, ... the risk of cross-contamination. ... 20ga Length: ...
Adult Bovine Serum US Origin...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
Biology Products: